ATE348101T1 - Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion - Google Patents

Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion

Info

Publication number
ATE348101T1
ATE348101T1 AT02766739T AT02766739T ATE348101T1 AT E348101 T1 ATE348101 T1 AT E348101T1 AT 02766739 T AT02766739 T AT 02766739T AT 02766739 T AT02766739 T AT 02766739T AT E348101 T1 ATE348101 T1 AT E348101T1
Authority
AT
Austria
Prior art keywords
inhibitors
phospphodiesterase
pde5
treatment
cardiovascular diseases
Prior art date
Application number
AT02766739T
Other languages
English (en)
Inventor
Jason Scott Sawyer
Mark W Orme
James D Copp
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Application granted granted Critical
Publication of ATE348101T1 publication Critical patent/ATE348101T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT02766739T 2001-04-25 2002-04-02 Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion ATE348101T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28673001P 2001-04-25 2001-04-25

Publications (1)

Publication Number Publication Date
ATE348101T1 true ATE348101T1 (de) 2007-01-15

Family

ID=23099912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02766739T ATE348101T1 (de) 2001-04-25 2002-04-02 Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion

Country Status (9)

Country Link
US (1) US7115621B2 (de)
EP (1) EP1383765B1 (de)
JP (1) JP4216606B2 (de)
AT (1) ATE348101T1 (de)
CA (1) CA2441792C (de)
DE (1) DE60216745T2 (de)
ES (1) ES2278956T3 (de)
MX (1) MXPA03009750A (de)
WO (1) WO2002088123A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
JP4671123B2 (ja) 2003-06-23 2011-04-13 小野薬品工業株式会社 新規三環性複素環化合物
EA016575B1 (ru) * 2004-03-15 2012-06-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Производные карболина, полезные в ингибировании ангиогенеза
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8063214B2 (en) * 2004-10-28 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of tadalafil
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
ES2459742T3 (es) * 2004-12-22 2014-05-12 Ono Pharmaceutical Co., Ltd. Compuesto tricíclico y uso del mismo
EP1747779A1 (de) 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolinsulfonamid-Derivate als 5-HT6 Liganden
KR20080047375A (ko) * 2005-07-29 2008-05-28 콘서트 파마슈티컬즈, 인크. 약제 화합물
WO2007020521A1 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
WO2007110734A1 (en) * 2006-03-24 2007-10-04 Glenmark Pharmaceuticals Limited Process for the preparation of tadalafil
WO2009038764A1 (en) * 2007-09-20 2009-03-26 D2E, Llc Fluoro-containing derivatives of hydrogented pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
EP2448585B1 (de) * 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinon-substituiertes azepin[b]indol und pyrido-pyrrolo-azepin mch-1 antagonisten, verfahren zur herstellung und verwendung davon
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
EP2687531B1 (de) 2011-03-18 2016-07-13 ONO Pharmaceutical Co., Ltd. Tetrahydrocarbolinderivat
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
TW201710258A (zh) 2015-06-23 2017-03-16 碩騰服務公司 咔啉抗寄生蟲藥

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES273769A1 (es) * 1961-01-18 1962-06-01 Geigy Ag J R Procedimiento para la preparaciën de nuevos derivados de amidas de acido beta-carbolin-carboxilico
JPS5543475B2 (de) * 1972-09-14 1980-11-06
US4336260A (en) * 1977-12-08 1982-06-22 The Dow Chemical Company Method and compositions using 1-aryl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid for treating depression
JPS5936676A (ja) * 1982-08-20 1984-02-28 Tanabe Seiyaku Co Ltd β−カルボリン誘導体の新規製法
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
AU710079B2 (en) * 1996-04-04 1999-09-16 F. Hoffmann-La Roche Ag Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
AU711885B2 (en) * 1996-05-10 1999-10-21 Icos Corporation Carboline derivatives
WO1997043267A1 (en) 1996-05-11 1997-11-20 Kings College London Pyrazines
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
EP1114048A1 (de) * 1998-09-16 2001-07-11 Agnès Bombrun Carbolin-derivate als cgmp phosphodiesterase-inhibitoren
DZ3179A1 (fr) * 1999-08-03 2001-02-08 Lilly Icos Llc Compositions pharmaceutiques à base de beta-carboline.
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
CA2411008C (en) * 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
EP1289990A1 (de) 2000-06-08 2003-03-12 Lilly Icos LLC Tetrazyklische diketopierazin verbidnungen als pdev inhibitoren
US6858620B2 (en) * 2000-10-03 2005-02-22 Lilly Icos, Llc Condensed pyridoindole derivatives
US6878711B2 (en) 2000-11-06 2005-04-12 Lilly Icos Llc Indole derivatives as PDE5-inhibitors

Also Published As

Publication number Publication date
US20040147542A1 (en) 2004-07-29
MXPA03009750A (es) 2004-06-30
JP2004532852A (ja) 2004-10-28
CA2441792C (en) 2010-08-03
WO2002088123A1 (en) 2002-11-07
EP1383765B1 (de) 2006-12-13
DE60216745D1 (de) 2007-01-25
CA2441792A1 (en) 2002-11-07
EP1383765A1 (de) 2004-01-28
ES2278956T3 (es) 2007-08-16
JP4216606B2 (ja) 2009-01-28
US7115621B2 (en) 2006-10-03
DE60216745T2 (de) 2007-05-16

Similar Documents

Publication Publication Date Title
DE60216745D1 (de) Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion
EA200200208A1 (ru) Синергитическая композиция
ATE302775T1 (de) Carbolinderivate
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
EA200700099A1 (ru) Производные пиридина
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
ECSP055809A (es) Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4
ATE346067T1 (de) Carbolinderivate
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
ATE332903T1 (de) Kondensierte pyridoindolderivate
MXPA05012247A (es) Derivados de bencimidazol nuevos.
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
ATE389655T1 (de) Pyrimidinderivate
ATE302776T1 (de) Kondensierte pyridoindolderivate
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DE60226970D1 (de) Pyrazinoä1',2':1,6ü-pyridoä3,4-bü indole-1,4-dionderivate
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
MXPA03004023A (es) Compuestos quimicos.
ATE297926T1 (de) Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties